<< Married men more likely to seek professional healthcare compared to single counterparts | iCo Therapeutics announces $4,000,000 brokered private placement >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

Published on October 31, 2009 at 1:58 AM · No Comments

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

Embozene(TM) Color-Advanced Microspheres are spherical embolics approved in Europe for the treatment of liver cancer, uterine fibroids, tumors of the head, neck, torso, and skeletal system; for bleeding and trauma, including nosebleeds; and for reducing the amount of bleeding before any surgery other than in the central nervous system.

"Physicians use microspheres to stop bleeding before a procedure, such as the removal of a tumor, but no one to date has been able to create a microsphere that fits larger blood vessels," said Thomas A. Gordy, President and Chief Executive Officer of CeloNova. "We developed this 2800 micron size to meet the needs of interventional radiologists."

In Europe, CeloNova currently offers 10 highly calibrated sizes of Embozene(TM) Microspheres in range from 40 microns to 1300 microns, making it one of the most versatile embolics in the market. The new 2800 micron size will be the largest microsphere available to physicians.

SOURCE CeloNova BioSciences, Inc.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading